Crispr Therapeutics (CRSP) has disclosed a new risk, in the Innovation / R&D category. Crispr Therapeutics faces a significant business risk due ...

Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making ...

Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate ...

The acceptability of biosimilars is certainly higher in the domestic market. Biosimilar substitution is automatic, which can take place as soon as a biosimilar is launched. The choice of a ...

It has been cleared with interchangeable status, meaning that pharmacists in the US will be able to substitute the biosimilar for Soliris at the point of dispensing, without consulting the prescriber.

As of today, July 1st, Cyltezo (adalimumab-adbm) is commercially available in the U.S. It is the first and thus far only therapeutically interchangeable Humira-referenced biosimilar approved by ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion. Late last week ...